Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease

Subir Roy, David Hemsell, Stephen Gordon, David Godwin, Mark Pearlman, David Luke

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND: Trovafloxacin is a new fourth-generation fluoroquinolone whose pharmacokinetics and in vitro activity suggest that it is well suited for antibiotic prophylaxis in elective hysterectomy. METHODS: In a randomized, double-blind, multicenter study, parallel groups of women 18 years of age or older received either 200 mg trovafloxacin by mouth and intravenous (IV) placebo or 2 g cefoxitin by IV infusion and placebo by mouth before elective vaginal or abdominal hysterectomy for nonmalignant disease. RESULTS: In the 103 and 97 patients in the trovafloxacin and cefoxitin groups, respectively, who were evaluable for efficacy, the prophylactic success rates at hospital discharge (96% in both groups) and 30 ± 6 days after hysterectomy (88% and 91% in the trovafloxacin and cefoxitin groups, respectively) were statistically equivalent. Both antibiotics were well tolerated. CONCLUSION: A single oral 200 mg dose of trovafloxacin is as effective and safe as a standard cefoxitin parenteral regimen in the prevention of primary bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease.

Original languageEnglish (US)
JournalAmerican Journal of Surgery
Volume176
Issue number6 A
DOIs
StatePublished - Dec 1998

Fingerprint

Cefoxitin
Hysterectomy
Bacterial Infections
Mouth
Placebos
Antibiotic Prophylaxis
Fluoroquinolones
Primary Prevention
Double-Blind Method
Intravenous Infusions
Multicenter Studies
Pharmacokinetics
trovafloxacin
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Surgery

Cite this

Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease. / Roy, Subir; Hemsell, David; Gordon, Stephen; Godwin, David; Pearlman, Mark; Luke, David.

In: American Journal of Surgery, Vol. 176, No. 6 A, 12.1998.

Research output: Contribution to journalArticle

@article{62c725250de64fb6a491233bfb7e7500,
title = "Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease",
abstract = "BACKGROUND: Trovafloxacin is a new fourth-generation fluoroquinolone whose pharmacokinetics and in vitro activity suggest that it is well suited for antibiotic prophylaxis in elective hysterectomy. METHODS: In a randomized, double-blind, multicenter study, parallel groups of women 18 years of age or older received either 200 mg trovafloxacin by mouth and intravenous (IV) placebo or 2 g cefoxitin by IV infusion and placebo by mouth before elective vaginal or abdominal hysterectomy for nonmalignant disease. RESULTS: In the 103 and 97 patients in the trovafloxacin and cefoxitin groups, respectively, who were evaluable for efficacy, the prophylactic success rates at hospital discharge (96{\%} in both groups) and 30 ± 6 days after hysterectomy (88{\%} and 91{\%} in the trovafloxacin and cefoxitin groups, respectively) were statistically equivalent. Both antibiotics were well tolerated. CONCLUSION: A single oral 200 mg dose of trovafloxacin is as effective and safe as a standard cefoxitin parenteral regimen in the prevention of primary bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease.",
author = "Subir Roy and David Hemsell and Stephen Gordon and David Godwin and Mark Pearlman and David Luke",
year = "1998",
month = "12",
doi = "10.1016/S0002-9610(98)00222-0",
language = "English (US)",
volume = "176",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "6 A",

}

TY - JOUR

T1 - Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease

AU - Roy, Subir

AU - Hemsell, David

AU - Gordon, Stephen

AU - Godwin, David

AU - Pearlman, Mark

AU - Luke, David

PY - 1998/12

Y1 - 1998/12

N2 - BACKGROUND: Trovafloxacin is a new fourth-generation fluoroquinolone whose pharmacokinetics and in vitro activity suggest that it is well suited for antibiotic prophylaxis in elective hysterectomy. METHODS: In a randomized, double-blind, multicenter study, parallel groups of women 18 years of age or older received either 200 mg trovafloxacin by mouth and intravenous (IV) placebo or 2 g cefoxitin by IV infusion and placebo by mouth before elective vaginal or abdominal hysterectomy for nonmalignant disease. RESULTS: In the 103 and 97 patients in the trovafloxacin and cefoxitin groups, respectively, who were evaluable for efficacy, the prophylactic success rates at hospital discharge (96% in both groups) and 30 ± 6 days after hysterectomy (88% and 91% in the trovafloxacin and cefoxitin groups, respectively) were statistically equivalent. Both antibiotics were well tolerated. CONCLUSION: A single oral 200 mg dose of trovafloxacin is as effective and safe as a standard cefoxitin parenteral regimen in the prevention of primary bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease.

AB - BACKGROUND: Trovafloxacin is a new fourth-generation fluoroquinolone whose pharmacokinetics and in vitro activity suggest that it is well suited for antibiotic prophylaxis in elective hysterectomy. METHODS: In a randomized, double-blind, multicenter study, parallel groups of women 18 years of age or older received either 200 mg trovafloxacin by mouth and intravenous (IV) placebo or 2 g cefoxitin by IV infusion and placebo by mouth before elective vaginal or abdominal hysterectomy for nonmalignant disease. RESULTS: In the 103 and 97 patients in the trovafloxacin and cefoxitin groups, respectively, who were evaluable for efficacy, the prophylactic success rates at hospital discharge (96% in both groups) and 30 ± 6 days after hysterectomy (88% and 91% in the trovafloxacin and cefoxitin groups, respectively) were statistically equivalent. Both antibiotics were well tolerated. CONCLUSION: A single oral 200 mg dose of trovafloxacin is as effective and safe as a standard cefoxitin parenteral regimen in the prevention of primary bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease.

UR - http://www.scopus.com/inward/record.url?scp=0032459108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032459108&partnerID=8YFLogxK

U2 - 10.1016/S0002-9610(98)00222-0

DO - 10.1016/S0002-9610(98)00222-0

M3 - Article

C2 - 9935259

AN - SCOPUS:0032459108

VL - 176

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 6 A

ER -